The U.S. now has another PD-1/L1 inhibitor—its seventh—thanks to an FDA go-ahead for GlaxoSmithKline’s Jemperli in an indication where Merck & Co.’s market-leading Keytruda has been around for years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback